27Apr 2024
Lupin Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Suspension

Lupin Receives FDA Approval for Generic Loteprednol Etabonate Ophthalmic Suspension

Lupin Limited announces FDA approval for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.5%, a generic equivalent to Lotemax® Ophthalmic Suspension, 0.5%, by Bausch & Lomb Inc. The product, manufactured in Lupin's Pithampur facility in India, is indicated for temporary relief of seasonal allergic conjunctivitis symptoms. Lotemax® had estimated annual sales of USD 59 million in the U.S. This approval enhances Lupin's portfolio and underscores its commitment to providing affordable healthcare solutions.

  • #family health

Like

Save

Share